ClinicalTrials.gg
RecruitingNCT06455280SET-SAILUpdated Nov 24, 2025

A Study of SIPLIZUMAB in AILD and LT Patients

A Phase 1 interventional study of Siplizumab in Autoimmune Liver Disease, Liver Transplant Disorder and Autoimmune Hepatitis, sponsored by Elizabeth C. Verna. Recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-11-24.

Sponsored by Elizabeth C. Verna · Phase 1, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Sep 2024; still recruiting 2 years 2 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
8
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 21 studies in Hepatitis, Autoimmune with a site in United States — 7 open to participants now, 8 under way, 1 of them phase 3. Hepatitis, Autoimmune · United States.

Planned enrollment
11th of 13
8 · median 24
Started
2024
with 1 other
Phase 1
5 of 21
1 open now
Registered
20th of 21
by date
Lead sponsor
1 of 21
Elizabeth C. Verna

Among the 21 studies in Hepatitis, Autoimmune with a site in United States, this one is the 11th largest by planned enrollment of the 13 interventional ones that give a count, is one of 2 that started in 2024, is one of 5 in phase 1, and was the 20th registered.

Hepatitis, Autoimmune

82 studies on the registry are indexed under Hepatitis, Autoimmune; 24 are open to participants now.

Browse Hepatitis, Autoimmune studies →

Open to participants now

7 of the 21 studies in Hepatitis, Autoimmune with a site in United States are open now. Recruiting first, the newest first:

1 more — sign in →

All 7 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 16 Hepatitis, Autoimmune studies recruiting now, 9 (56%) set no upper age limit and 4 (25%) stop at 75 or younger; 8 take children under 18; 5 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 21 studies in Hepatitis, Autoimmune with a site in United States, or all of them as a file.
02

Study summary

There is a significant unmet need for safe and effective therapeutic approaches to prevent immune-mediated graft injury and its complications in liver transplant (LT) recipients with autoimmune liver disease (AILD) including autoimmune hepatitis and primary sclerosing cholangitis. Siplizumab is an anti-cluster of differentiation 2 (CD2) monoclonal antibody that has demonstrated a favorable safety profile of siplizumab in over 779 human subjects and has been shown to target memory T cells-a key driver in the immune processes surrounding rejection and autoimmunity post LT in AILD. The purpose of this pilot, open-label phase 1 study is to determine the safety of siplizumab for induction in patients with AILD undergoing LT.

Up to eight (8) subjects will receive siplizumab 0.6 mg/kg/dose on the day of transplant (Day 0) and Day 4 post-transplant, for a total of two doses.

All subjects will be followed in the study for 12 months post-LT.

Read the detailed description

The purpose of this study is to evaluate the safety of siplizumab when used as induction immunosuppression in patients with primary sclerosing cholangitis (PSC) or autoimmune hepatitis (AIH) undergoing liver transplantation. Induction immunosuppression drugs are very potent anti-rejection drugs that are given immediately after transplantation to prevent rejection. Siplizumab is investigational, meaning it has not yet been approved for market use for this disease condition by the United States Food and Drug Administration (FDA).

Adult patients (18 years of age and older) listed for LT with the specific AILD diagnoses of PSC or AIH

All subjects will receive 0.6 mg/kg/dose intravenously on the day of transplant (Day 0) intraoperatively and on post-transplant Day 4.

Participation in this study will last approximately 15 months (\~ 3 months on the LT waitlist, up to 12 months participation post-LT)

03

Conditions studied

  • Autoimmune Liver Disease
  • Liver Transplant Disorder
  • Autoimmune Hepatitis
  • Primary Sclerosing Cholangitis
  • End Stage Liver DIsease
  • Cirrhosis, Liver

Keywords

  • Autoimmune Liver Disease
  • Liver Transplant Disorder
  • Autoimmune Hepatitis
  • Primary Sclerosing Cholangitis
  • End Stage Liver DIsease
  • Cirrhosis, Liver
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Able to provide
  2. Age ≥ 18 years old
  3. Clinical diagnosis of AIH and/or PSC
  4. Listed for liver transplantation
  5. Epstein-Barr virus (EBV) seropositive within 12 months of screening

Exclusion criteria

Exclusion Criteria:

  1. Presence or history of significant liver disease other than AIH or PSC, including viral hepatitis, alcohol-related liver disease and -proven non-alcoholic steatohepatitis
  2. Prior transplant
  3. Listed for multiorgan transplant
  4. Acute liver failure
  5. Known , including cholangiocarcinoma and hepatocellular carcinoma
  6. Other products in the last 30 days or 5 half lives
  7. Pregnant/lactating or unwilling to use
  8. Leukopenia (WBC less than 2,000/mm3
  9. Absolute lymphocyte count \< 200/mm3
  10. Sero-positive for -1
  11. Virus (HCV) antibody or RNA positive (within 6 months of screening)
  12. , hepatitis B virus (HBV) DNA or HBcAb positive (within 6 months of screening)
  13. Alcohol use exceeding 30g/day for men or 20g/day for women, and/or known phosphatidylethanol (PETH) level >80 in the 3 months prior to LT
  14. Untreated latent TB infection as detected by QuantiFERON Gold Plus Interferon Gamma Release Assay (IGRA) (or current standard interferon gamma release assay for TB)
  15. Receipt of any within 2 months of transplant.

ADDITIONAL exclusion criteria to be reviewed at the time of transplant

  1. Renal failure with dialysis or with estimated (eGFR) \< 30 at the time of LT
  2. Model for end-stage liver disease (MELD)-Na score >30
  3. Donor features of Donation after Cardiac Death (DCD), HCV Ab or nucleic acid testing (NAT+), HBcAb or HBsAg+, or blood types A, B, and O incompatible organ
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
8 participants (estimated)

Study arms

  • Experimental
    Open Label

    subjects will receive 0.6 mg/kg/dose intravenously on the day of transplant (Day 0) intraoperatively and on post-transplant Day 4.

    Drug: Siplizumab

Interventions

  • Siplizumab is an anti-CD2 monoclonal antibody that has demonstrated a favorable safety profile of siplizumab in over 779 human subjects and has been shown to target memory T cells-a key driver in the immune processes surrounding rejection and autoimmunity post LT in AILD.

06

What researchers measure

Primary outcomes

  1. Serious infection in the first month post-transplant,

    viral, bacterial or fungal infection that leads to readmission, prolonged hospitalization, reoperation, intensive care unit admission, graft loss or death.

    Time frame: 1 Month post-transplant

Secondary outcomes

  1. Incidence of immune-mediated liver injury

    biopsy proven acute rejection (BPAR), or recurrent AILD

    Time frame: 12 month Post-transplant

  2. Incidence of graft loss or death

    Loss of liver allograft or incidence of mortality

    Time frame: 12 month Post-transplant

  3. Incidence of BPAR

    biopsy proven acute rejection within 12 Month post-transplant

    Time frame: 12 month Post-transplant

  4. Incidence of treated BPAR

    biopsy proven acute rejection that requires treatment within 12 Month post-transplant

    Time frame: 12 month Post-transplant

  5. Incidence of refractory BPAR

    biopsy proven acute rejection within 12 Month post-transplant that is not responsive to treatment

    Time frame: 12 month Post-transplant

  6. Incidence of development of donor specific antibodies (DSA)

    Donor specific antibodies within 12 Month Post-transplant

    Time frame: 12 month Post-transplant

  7. Incidence of recurrent AILD

    based upon histology for autoimmune hepatitis \[AIH\] and histology and/or imaging for primary sclerosing cholangitis \[PSC\]

    Time frame: 12 month Post-transplant

Other outcomes

  1. Peak plasma concentration (Cmax) after single dose of siplizumab

    Cmax after single dose

    Time frame: 12 hours Post-treatment

  2. The area under the curve (AUC) from time zero to the last measurable plasma concentration sampling time.

    AUC based on plasma concentrations over 84 days post-treatment

    Time frame: 84 Days Post-transplant

  3. Descriptive summary statistics by dosing level and visit/sampling time point

    the frequency of siplizumab concentrations below the lower-limit of quantification (LLOQ)

    Time frame: 12 month Post-transplant

  4. Summary statistics of pharmacokinetic (PK) of Siplizumab

    mean, standard deviation (SD), coefficient of variation (CV), median, minimum and maximum of siplizumab concentrations.

    Time frame: 12 month Post-transplant

  5. Change in Concentration T-Cells

    Change in Concentration of T- cells (cells/uL)

    Time frame: 12 month Post treatment

  6. Change in Concentration of B- cells

    Change in Concentration of B- cells (cells/uL)

    Time frame: 12 month Post treatment

  7. Change in Concentration of NK- cells

    Change in Concentration of NK- cells (cells/uL)

    Time frame: 12 month Post treatment

  8. CD2 receptor occupancy by dose level and subject

    Measurement of CD2 receptor occupancy

    Time frame: 12 month Post-transplant

  9. Dynamics of T-cell subset recovery in the blood and allograft liver

    Measurement of T-cell subset in the blood and allograft liver

    Time frame: 12 month Post-transplant

07

Study locations

1 of 1 sites recruiting
  • Columbia University Irving Medical Center/NewYork-Presbyterian Hospital
    New York, New York 10032, United States
    Recruiting
    • Theresa Lukose, PharmD · Contacttt2103@cumc.columbia.edu · 212-305-3839
    • Elizabeth Verna, MD · Principal investigator
08

References and documents

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Sep 2024 (actual). Primary completion is estimated for Dec 2027, 39 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 7, 2024
First posted
Jun 12, 2024
StartActual
Sep 11, 2024
Primary completionEst.
Dec 31, 2027
CompletionEst.
Mar 31, 2028
Last update
Nov 24, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 24, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06455280
Lead sponsor
Elizabeth C. Verna
Collaborators
ITB-Med LLC
Responsible party
Elizabeth C. Verna (Frank Cardile Associate Professor of Medicine, Columbia University) — Sponsor-investigator
First posted
Jun 12, 2024
Start date
Sep 11, 2024
Primary completion
Dec 31, 2027 (estimated)
Completion
Mar 31, 2028 (estimated)
Last update
Nov 24, 2025

Study contacts

Theresa Lukose, PharmD
Contact
tt2103@cumc.columbia.edu
212-305-3839
Amanda Alonso, MHA
Contact
aa2974@cumc.columbia.edu
212-342-0261
Elizabeth Verna, MD
principal investigator · Columbia University Irving Medical Center/ New York Presbyterian Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Siplizumab

Start the discussion